An overview of prospective drugs for type 1 and type 2 diabetes.
This study provided an overview of several emerging anti-diabetic molecules. Diabetes is a complex metabolic disorder involving dysregulation of glucose homeostasis at various levels. Insulin, which is produced by β-pancreatic cells, is a chief orchestrator of glucose metabolism, regulating its consumption within cells, which leads to energy generation or storage as glycogen. Abnormally lower insulin secretion from β-cells, insulin insensitivity, and insulin tolerance lead to higher plasma glucose levels, resulting in metabolic complications. The last century has witnessed extraordinary efforts by the scientific community to develop anti-diabetic drugs, and these efforts yielded the discovery of exogenous insulin and various classes of oral anti-diabetic drugs. Despite these exhaustive anti-diabetic pharmaceutical and therapeutic efforts, long-term glycemic control, hypoglycemic crisis, safety issues, large-scale economic burden, side effects remain core problems. The last decade has witnessed the development of various new classes of anti-diabetic drugs with different pharmacokinetic and pharmacodynamics profiles. Details of their FDA approvals and advantages/disadvantages are summarized in this review, Result: Salient features of insulin degludec, sodium glucose co-transporter 2 inhibitors, glucokinase activators, fibroblast growth factor 21 receptor agonists, and GLP-1 agonists are discussed. In the future, these new anti-diabetic drugs should have broad clinical applicability.